Actively Recruiting
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
Led by Beth Israel Deaconess Medical Center · Updated on 2024-05-09
98
Participants Needed
1
Research Sites
315 weeks
Total Duration
On this page
Sponsors
B
Beth Israel Deaconess Medical Center
Lead Sponsor
M
Massachusetts Institute of Technology
Collaborating Sponsor
AI-Summary
What this Trial Is About
This research is studying a new investigative imaging instrument called a nonlinear microscope (NLM). A nonlinear microscope can produce images similar to an ordinary pathologist's microscope, but without first processing tissue to make slides. This study will determine if a NLM can be used to evaluate tissue during lumpectomy surgery for breast cancer in order to reduce the probability that standard pathologic examination of the specimen after the end of the operation will find close or positive margins, thus possibly requiring the patient to have additional breast surgery.
CONDITIONS
Official Title
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female patients scheduled for lumpectomy for breast cancer at BIDMC
- Core needle biopsy showing invasive breast cancer or ductal carcinoma in situ (DCIS)
- At least 21 years old
- Eligible for breast conserving surgery, lumpectomy, and radiation
- Estrogen receptor positive (ER+) on biopsy, or if ER negative, with evaluable estrogen receptor status and positive internal control
- Progesterone receptor positive (PR+) if biopsy shows invasive cancer, or if PR negative, with evaluable progesterone receptor status and positive internal control
- HER2 testing (IHC and/or FISH) done on biopsy if invasive cancer is present
- Oncotype DX or other genetic assay performed on biopsy or not requested
- Ability to understand and willing to sign informed consent
You will not qualify if you...
- Contraindicated for radiation therapy
- Pregnant women
- Current invasive cancer or DCIS at previous surgery site
- Received any systemic neoadjuvant or preoperative therapy between biopsy and lumpectomy
- Participation in another breast cancer treatment trial
- Risk of poor cosmetic outcome after lumpectomy and possible additional excision
- Recommendation for mastectomy based on radiology
- Complex DCIS requiring large tissue removal as indicated by radiology
- Missing or unclear ER, PR, or HER2 testing prior to surgery if invasive cancer is present
- Missing or unclear ER testing prior to surgery if DCIS is present
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02115
Actively Recruiting
Research Team
J
James Connolly, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here